Geneva Capital Management LLC lessened its position in shares of Novanta Inc. (NASDAQ:NOVT – Free Report) by 7.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 700,450 shares of the technology company’s stock after selling 58,428 shares during the period. Novanta accounts for 2.8% of Geneva Capital Management LLC’s holdings, making the stock its 8th biggest holding. Geneva Capital Management LLC’s holdings in Novanta were worth $99,597,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of NOVT. Bessemer Group Inc. grew its holdings in Novanta by 2.1% during the 3rd quarter. Bessemer Group Inc. now owns 196,975 shares of the technology company’s stock worth $28,008,000 after acquiring an additional 3,975 shares during the period. Hantz Financial Services Inc. lifted its stake in shares of Novanta by 6.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,274 shares of the technology company’s stock valued at $181,000 after purchasing an additional 78 shares during the period. Aberdeen Group plc acquired a new position in shares of Novanta in the 3rd quarter valued at about $552,152,000. Allworth Financial LP lifted its stake in shares of Novanta by 77.1% in the 3rd quarter. Allworth Financial LP now owns 641 shares of the technology company’s stock valued at $91,000 after purchasing an additional 279 shares during the period. Finally, Russell Investments Group Ltd. boosted its position in shares of Novanta by 20.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 33,437 shares of the technology company’s stock valued at $4,755,000 after purchasing an additional 5,702 shares in the last quarter. Institutional investors and hedge funds own 98.35% of the company’s stock.
Analyst Ratings Changes
Several equities research analysts recently commented on the company. Weiss Ratings cut Novanta from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, November 10th. Wall Street Zen downgraded Novanta from a “buy” rating to a “hold” rating in a report on Sunday. Zacks Research downgraded Novanta from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 6th. Finally, Robert W. Baird dropped their price target on Novanta from $194.00 to $175.00 and set an “outperform” rating on the stock in a research note on Thursday. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $175.00.
Get Our Latest Report on Novanta
Novanta Price Performance
Shares of NASDAQ NOVT opened at $118.88 on Monday. The firm has a market cap of $4.50 billion, a PE ratio of 90.75, a P/E/G ratio of 2.58 and a beta of 1.71. Novanta Inc. has a 12-month low of $98.27 and a 12-month high of $176.38. The company’s fifty day simple moving average is $140.29 and its 200 day simple moving average is $142.25. The company has a quick ratio of 0.76, a current ratio of 1.18 and a debt-to-equity ratio of 0.48.
Novanta (NASDAQ:NOVT – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The technology company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $0.97 by $0.08. The business had revenue of $305.01 million during the quarter, compared to analysts’ expectations of $301.02 million. Novanta had a net margin of 4.89% and a return on equity of 10.23%. The business’s quarterly revenue was up 23.1% on a year-over-year basis. During the same period last year, the company posted $0.87 earnings per share. As a group, sell-side analysts forecast that Novanta Inc. will post 3.68 earnings per share for the current fiscal year.
Novanta Company Profile
Novanta develops and manufactures precision technologies used in medical and advanced industrial applications. Its products include photonics and laser components, precision motion-control systems, machine-vision technologies, and related equipment and software. The company’s technologies are used in areas such as medical and surgical systems, life sciences, robotics, and industrial automation. Novanta serves customers internationally, with operations and customers across North America, Europe, and Asia.
Featured Stories
- Five stocks we like better than Novanta
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding NOVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novanta Inc. (NASDAQ:NOVT – Free Report).
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.
